Plasma Powerhouse

Plasma is the liquid component of human blood that acts as the body’s communication superhighway. A biological marvel, it transports essential elements that sustain healthy function, including blood cells, nutrients and, notably, proteins. Serving as the underlying supply chain to all organs, this unique life fluid is potentially the source of therapies for multiple diseases – and the key for enhanced quality of life. 

Our constantly evolving and growing understanding of the universe of circulating plasma proteins, known as the plasma proteome, has led to critical scientific advances and therapies enabling patients with chronic plasma-protein deficiencies to enjoy healthier, longer and more productive lives. Grifols continuously enhances its treatments, including immunoglobulins for primary and secondary immunodeficiencies, albumin for blood expansion in emergency and surgical medicine, and alpha-1 antitrypsin, indicated in respiratory patients to treat alpha-1 antitrypsin deficiency, among many others. We ensure the highest standards are met throughout the entire plasma journey, from plasma collection to the delivery of therapies to patients.

Combining cutting-edge artificial intelligence, bioanalytics and technology platforms such as those from our Alkahest subsidiary, we explore plasma at the furthest-known depths. Specifically, we look at the composition and concentration of people’s plasma proteins, or the entire universe of proteins called the plasma proteome. It shifts over time with age and illness, offering clues about a person’s present and future health – and giving us unique insights to develop potential transformative therapies.

An example of this work is our pioneering ‘Chronos-PD’ project, an initiative that aims to discover early biomarkers of Parkinson’s disease to inform the development of new diagnostic and early therapeutic approaches for this neurological condition affecting more than 6 million people worldwide.